Neurocrine Biosciences
NBIX
#1313
Rank
C$24.06 B
Marketcap
C$239.38
Share price
-0.39%
Change (1 day)
32.31%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2026 (TTM): C$9.27

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is C$9.40. In 2025 the company made an earnings per share (EPS) of C$6.75 an increase over its 2024 EPS that were of C$4.73.

EPS history for Neurocrine Biosciences from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)C$9.2737.27%
2025C$6.7542.6%
2024C$4.7333.07%
2023C$3.5657.76%
2022C$2.2669.47%
2021C$1.33-78.21%
2020C$6.11990%
2019C$0.5681.82%
2018C$0.31-113.5%
2017C-$2.280.62%
2016C-$2.2757.28%
2015C-$1.4425.61%
2014C-$1.1518.84%
2013C-$0.97-1085.71%
2012C$0.09806

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
C$1.84-80.48%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
C$2.88-69.35%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
C$39.54 320.65%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
C$1.29-86.29%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
C-$2.84-130.25%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
C$4.90-47.84%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
C-$41.89-545.60%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
C$2.67-71.62%๐Ÿ‡ฌ๐Ÿ‡ง UK